Katherine Fuh, MD, PhD

Complete response of somatic POLE-ultramutated recurrent undifferentiated uterine sarcoma to pembrolizumab and concurrent radiotherapy.

Correction: GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive "targeted" surgery?

DDR2 confers ferroptosis resistance to cancer-associated fibroblasts and attenuates PARPi sensitivity of ovarian tumor cells.